Orban Biotech said that the QTDP covers funding for a therapeutic insulin B chain vaccine to treat type 1 diabetes mellitus.
The company claims that its insulin B chain vaccine is designed to function by re-establishing self-tolerance towards insulin, thus arresting autoimmune destruction and preserving self-insulin production.
Orban Biotech CEO Tihamer Orban said that they are pleased that Orban Biotech’s therapeutic vaccine has been recognised by this program for its potential to treat type 1 diabetes and other autoimmune disorders.
"Our insulin B chain drug has already completed a Phase I study with promising results and the drug is now poised to move into a Phase II study," Orban said.